Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Released On
September 30, 2023
Expires On
September 30, 2024
Media Type
Internet
Completion Time
45 minutes
Specialty
Emergency Medicine, Hematology-Oncology, Hepatology, Pathology, Pediatrics, Pharmacy, Primary Care
Topic(s)
Leukemia
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This educational activity is supported by an educational grant from Abbvie.
Credit Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
- Nurses - 0.75 including 0.50 pharmacology hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity was developed for hematologist-oncologists, hematology advanced practitioners, hematology nurses, pathologists, emergency medicine physicians, pediatricians, primary care physicians, pharmacists, and other clinicians who diagnose or treat patients with acute myeloid leukemia.
Program Overview
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-selectin, and SMO. Dr. Jonas utilizes case studies to share his insights in the treatment of patients with AML.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe current and emerging molecular features and targets in acute myeloid leukemia (AML) that impact therapeutic decisions
- Optimize treatment plans for patients with newly diagnosed AML, including those appropriate and inappropriate for intensive treatment
- Develop personalized guideline-recommended treatment plans for patients with relapsed/refractory AML
Faculty
Brian Jonas, MD, PhD
Professor of Medicine
University of California, Davis
Davis, California
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit
The Annenberg Center designates this enduring material for a maximum 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Credit
The Annenberg Center designates this education for a maximum of 0.75 American Nurses Credentialing Center (ANCC) contact hour, including 0.50 pharmacology hour.
Disclosures of Conflicts of Interest
- Brian Jonas, MD, PhD
- Consultant: AbbVie, BMS, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Kymera, Rigel, Servier
- Research Support: AbbVie, Amgen, AROG, Aptose, BMS, Celgene, F. Hoffmann-La Roche, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immun-Onc, Jazz, Loxo, Pfizer, Pharmacyclics, Treadwell
Additional content planners
The following have no significant relationship to disclose:
Kimberly Tyler, ANP-C, AOCNP (Medical Writer)
Eugene Cullen, MD (Peer Reviewer)
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Planner)
The following have no relevant financial relationship to disclose:
Sunali Wadehra, MD Medical Writer
Kam Newman, MD (Peer Reviewer)
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Planner)
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].